SuperworthRafael RFL
- Market cap
- $68.1M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 69.5×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $980K
- +34% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- n/m
- not a meaningful number
Rafael trades at 69.5× sales. Its trailing earnings are negative, so it has no PE. Revenue was $980K over the last twelve months, up 34% on a year earlier.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $68K−1% | $68K−3% | $68K−3% | $336K+373% | $165K+143% | $128K+88% | $77K+13% | $362K+8% | $350K+112% | $240K+88% | $211K+174% | $179K−51% | |
| Cost of revenue | n/a | n/a | n/a | $85K | $69K | $37K | $38K | $40K−53% | $19K−73% | $9K−76% | $12K−68% | $8K−80% |
| Gross profit | n/a | n/a | n/a | $251K | $96K | $91K | $39K | $322K+28% | $331K+245% | $231K+154% | $199K+410% | $171K−47% |
| R&D | $1.3M−31% | $489K−77% | $612K−73% | $1.5M+106% | $1.5M+22% | $1.3M+171% | $947K+55% | $3M+97% | $7.5M+389% | $7.5M+464% | $4.5M+378% | $4.9M+62% |
| SG&A | $1.4M−54% | $2M−34% | $2.6M+23% | $1.9M−18% | $2.3M+67% | $2.5M+24% | $2.6M+1% | $3.2M+65% | $5.5M+136% | $2.8M+13% | $2.3M−12% | $2.1M−33% |
| −$2.6M−46% | −$2.5M−52% | −$3.1M−26% | −$93.2M+2974% | −$3.8M+47% | −$3.8M+55% | −$6.6M+111% | −$5.9M−94% | −$12.8M+232% | −$10.1M+164% | −$6.7M+0% | −$6.9M+16% | |
| Interest expense | n/a | n/a | n/a | $85K | $163K | $162K | $163K | $165K+94% | $168K+3% | $160K−1% | $161K−1% | $6K−96% |
| Pre-tax income | $1.5M | −$3.5M−32% | $6.1M | −$64.9M+3589% | −$4.9M | −$9.2M+160% | −$5.3M | −$6.5M−90% | −$12.2M+148% | −$9.8M+6% | −$6.3M+18% | −$2.9M−55% |
| $4K | $6K+20% | $0 | −$2.6M+866% | −$87K | $12K+100% | $20K | −$2.4M−7% | −$174K+100% | $10K−17% | $48K+140% | $6K | |
| Net income | $1.2M | −$3.6M | $6M | −$32.4M+2151% | −$4.5M | −$9M+148% | −$4.6M | −$4.8M−85% | −$12.1M+171% | −$9.8M+9% | −$6.4M+38% | −$4.2M−12% |
| $0.05 | −$0.15 | $0.25 | −$1.36+2167% | −$0.19 | −$0.37+147% | −$0.19 | −$0.19−86% | −$0.29+53% | −$0.19−49% | −$0.13−32% | −$0.08−58% | |
| 23.5M+14% | 23.6M+3% | 24.4M+5% | 23.8M+2% | 23.9M+2% | 24.1M+2% | 24.2M−1% | 25.2M+6% | 42.2M+76% | 51.2M+113% | 51.2M+112% | 51.2M+103% |
Revenue: Q1 FY17: 6 months less the 3 months printed beside them.
Gross profit: 9 periods, Q3 FY24 to Q3 FY26: not printed by the filing, worked out from its own lines.
SG&A: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Operating income: Q1 FY17: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY17: 6 months less the 3 months printed beside them.
Income tax: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Net income: Q1 FY17: 6 months less the 3 months printed beside them.
EPS, diluted: 14 periods, Q4 FY17 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 8 periods, Q4 FY17 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY23: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Rafael's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| RFLRafael | $68.1M | n/m | 18.2× | 69.5× | +34% | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| Peer median | $477.3M | 10.5× | 12.3× | 1.4× | +2% | 13.6% |
More on Rafael
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .